爱尔兰戈尔韦 - 市值达1154.2亿美元的医疗设备与用品行业领军企业Medtronic plc（NYSE:MDT）宣布，其创新型BrainSense™自适应脑深部刺激（aDBS）系统和BrainSense™电极识别器（EI）已获得FDA批准，可用于治疗美国帕金森病患者。根据InvestingPro数据显示，该公司保持着强劲的财务健康状况，为持续推进医疗技术创新奠定了良好基础。这项突破性技术能够根 ...

Starting today, people with Parkinson's disease will have a new treatment option, thanks to U.S. Food and Drug Administration ...

The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever ...

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...

New Delhi: Adaptive and personalised deep brain stimulation can be more effective in controlling symptoms of Parkinson’s disease than standard deep brain stimulation (DBS), an established ...